表紙
市場調査レポート

Affimed Therapeutics AG - 製品パイプラインレビュー

Affimed Therapeutics AG - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224701
出版日 ページ情報 英文 25 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Affimed Therapeutics AG - 製品パイプラインレビュー Affimed Therapeutics AG - Product Pipeline Review - 2015
出版日: 2015年03月26日 ページ情報: 英文 25 Pages
概要

Affimed Therapeutics AG は、臨床病期に対応したバイオテクノロジー企業として、癌以外にも炎症疾患などの生命に関わる疾患を治療するための独自の抗体薬を開発しています。

当レポートでは、Affimed Therapeutics AGにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Affimed Therapeutics AGの基本情報

Affimed Therapeutics AGの概要

  • 主要情報
  • 企業情報

Affimed Therapeutics AG:R&Dの概要

  • 主な治療範囲

Affimed Therapeutics AG:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Affimed Therapeutics AG:パイプライン製品の概況

Affimed Therapeutics AG

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ

Affimed Therapeutics AG

  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

Affimed Therapeutics AG:薬剤プロファイル

  • FM-13
  • AFM-11
  • AFM-21

Affimed Therapeutics AG:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Affimed Therapeutics AG:最近のパイプライン動向

Affimed Therapeutics AG:休止中のプロジェクト

Affimed Therapeutics AG:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06888CDB

Summary

Global Markets Direct's, 'Affimed Therapeutics AG - Product Pipeline Review - 2015', provides an overview of the Affimed Therapeutics AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Affimed Therapeutics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Affimed Therapeutics AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Affimed Therapeutics AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Affimed Therapeutics AG's pipeline products

Reasons to buy

  • Evaluate Affimed Therapeutics AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Affimed Therapeutics AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Affimed Therapeutics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Affimed Therapeutics AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Affimed Therapeutics AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Affimed Therapeutics AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Affimed Therapeutics AG Snapshot
    • Affimed Therapeutics AG Overview
    • Key Information
    • Key Facts
  • Affimed Therapeutics AG - Research and Development Overview
    • Key Therapeutic Areas
  • Affimed Therapeutics AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Affimed Therapeutics AG - Pipeline Products Glance
    • Affimed Therapeutics AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Affimed Therapeutics AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Affimed Therapeutics AG - Drug Profiles
    • AFM-13
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AFM-11
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AFM-21
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Affimed Therapeutics AG - Pipeline Analysis
    • Affimed Therapeutics AG - Pipeline Products by Target
    • Affimed Therapeutics AG - Pipeline Products by Route of Administration
    • Affimed Therapeutics AG - Pipeline Products by Molecule Type
    • Affimed Therapeutics AG - Pipeline Products by Mechanism of Action
  • Affimed Therapeutics AG - Recent Pipeline Updates
  • Affimed Therapeutics AG - Dormant Projects
  • Affimed Therapeutics AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Affimed Therapeutics AG, Key Information
  • Affimed Therapeutics AG, Key Facts
  • Affimed Therapeutics AG - Pipeline by Indication, 2015
  • Affimed Therapeutics AG - Pipeline by Stage of Development, 2015
  • Affimed Therapeutics AG - Monotherapy Products in Pipeline, 2015
  • Affimed Therapeutics AG - Phase II, 2015
  • Affimed Therapeutics AG - Phase I, 2015
  • Affimed Therapeutics AG - Preclinical, 2015
  • Affimed Therapeutics AG - Pipeline by Target, 2015
  • Affimed Therapeutics AG - Pipeline by Route of Administration, 2015
  • Affimed Therapeutics AG - Pipeline by Molecule Type, 2015
  • Affimed Therapeutics AG - Pipeline Products by Mechanism of Action, 2015
  • Affimed Therapeutics AG - Recent Pipeline Updates, 2015
  • Affimed Therapeutics AG - Dormant Developmental Projects,2015
  • Affimed Therapeutics AG, Subsidiaries

List of Figures

  • Affimed Therapeutics AG - Pipeline by Top 10 Indication, 2015
  • Affimed Therapeutics AG - Pipeline by Stage of Development, 2015
  • Affimed Therapeutics AG - Monotherapy Products in Pipeline, 2015
  • Affimed Therapeutics AG - Pipeline by Top 10 Target, 2015
  • Affimed Therapeutics AG - Pipeline by Top 10 Route of Administration, 2015
  • Affimed Therapeutics AG - Pipeline by Top 10 Molecule Type, 2015
  • Affimed Therapeutics AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top